Mutations in this related ErbB family member have been described in 10% of unselected lung adenocarcinomas but, to date, not in patients treated with EGFR TKIs or agents targeting ErbB2. 30 The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results